UCB takes on Jazz in severe epilepsy with new Fintepla approval

UCB has won FDA approval for Fintepla as a treatment seizures associated with rare childhood epilepsy Lennox-Gastaut Syndrome (LGS), raising the pressure on Jazz Pharma’s rival therapy Epidiolex.